PCI Biotech Holding ASA (STU:4QG) 3-Year Book Growth Rate : -40.90% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PCI Biotech Holding ASA 3-Year Book Growth Rate?

PCI Biotech Holding ASA's Book Value per Share for the quarter that ended in Jun. 2023 was €0.11.

During the past 12 months, PCI Biotech Holding ASA's average Book Value per Share Growth Rate was -32.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -40.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was -36.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of PCI Biotech Holding ASA was 103.20% per year. The lowest was -53.90% per year. And the median was -25.80% per year.

Competitive Comparison of PCI Biotech Holding ASA's 3-Year Book Growth Rate

For the Biotechnology subindustry, PCI Biotech Holding ASA's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's 3-Year Book Growth Rate falls into.

PCI Biotech Holding ASA 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

PCI Biotech Holding ASA (STU:4QG) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

PCI Biotech Holding ASA 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA (STU:4QG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (STU:4QG) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

PCIB:Norway 4QG:Germany

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (STU:4QG) Headlines

No Headlines